Dataset Information

Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies.

ABSTRACT:

Background

Head and neck squamous cell carcinoma (HNSCC) is heterogeneous in etiology, phenotype and biology. Patient-derived xenografts (PDX) maintain morphology and molecular profiling of the original tumors and have become a standard "Avatar" model for human cancer research. However, restricted availability of tumor samples hindered the widespread use of PDX. Most PDX-projects include only surgical specimens because reliable engraftment from biopsies is missing. Therefore, sample collection is limited and excludes recurrent and metastatic, non-resectable cancer from preclinical models as well as future personalized medicine.

Methods

This study compares the PDX-take rate, -growth, histopathology, and molecular characteristics of endoscopic specimens with surgical specimens. HNSCC samples (n = 55) were collected ad hoc, fresh frozen and implanted into NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ mice.

Results

Engraftment was successful in both sample types. However, engraftment rate was lower (21 vs. 52%) and growth delayed (11.2 vs. 6.7 weeks) for endoscopic biopsies. Following engraftment, growth kinetic was similar. Comparisons of primary tumors and corresponding PDX models confirmed preservation of histomorphology (HE histology) and molecular profile (Illumina Cancer Hotspot Panel) of the patients' tumors. Accompanying flow cytometry on primary tumor specimens revealed a heterogeneous tumor microenvironment among individual cases and identified M2-like macrophages as positive predictors for engraftment. Vice versa, a high PD-L1 expression (combined positive score on tumor/immune cells) predicted PDX rejection.

Conclusion

Including biopsy samples from locally advanced or metastatic lesions from patients with non-surgical treatment strategies, increases the availability of PDX for basic and translational research. This facilitates (pre-) clinical studies for individual response prediction based on immunological biomarkers.

SUBMITTER: Struder D

PROVIDER: S-EPMC8344210 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Although preoperative chemoradiotherapy (CRT) and surgical mesorectal resection is the standard of care for locally advanced rectal carcinomas, it is still difficult to predict which patients will respond to treatment. We explored how differential stromal transcriptomic profiles from microdissected pretreatment rectal biopsies can be used to define an immunohistochemical score based on two CAF-specific proteins for predicting neoadjuvant treatment response. The analysis of differentially expressed genes (DEGs) of stroma and tumour glands from responder and non-responder patients shows that most changes were associated with the stromal compartment. Gene ontology analysis revealed that the DEGs codify mainly for extracellular matrix and ribosomal components. We built a CAF-specific classifier with genes showing monotonic changes in expression according to the tumour regression grade (coefficient >1; FN1, COL3A1, COL1A1, MMP2 and IGFBP5). These are the genes that display the biggest a priori differences in expression between non-responder and responder stroma. We translated these five genes at the protein level by means of immunohistochemical staining in a cohort of 38 patients. For predictive purposes we used a leave-one-out cross-validated (LOOCV) model with a positive predictive value (PPV) of 80%. Classifier optimisation with Random Forest identified FN1 and COL3A1 as the best predictors. Rebuilding the LOOCV regression model improved the classification performance with a PPV of 89.5% and a negative predictive value (NPV) of 73.7%. An independent cohort of 36 patients was used to validate the classifier performance, which had a PPV of 84.2% and an NPV of 70.6%. In a multivariate analysis the two-protein classifier proved to be the only independent predictor of response (HR=2.58; P=0.003). We also explored a pharmacogenomic approach to gather information about possible therapeutic strategies for non-responder patients. In conclusion, we developed a two-protein immunohistochemical classifier that performs well at predicting the absence of response to neoadjuvant treatment in rectal cancer.